Epitope Conservation of AZD5148, a Broadly Neutralizing Anti-Toxin B Monoclonal Antibody, Among Diverse and Global Contemporary Clostridioides difficile Isolates - Scorecard - MDSpire
Advertisement
Epitope Conservation of AZD5148, a Broadly Neutralizing Anti-Toxin B Monoclonal Antibody, Among Diverse and Global Contemporary Clostridioides difficile Isolates
Clinical Scorecard: Conservation of the Binding Epitope for AZD5148, a Broadly Neutralizing Monoclonal Antibody Against Toxin B, Across Diverse Global Clostridioides difficile Strains
At a Glance
Category
Detail
Condition
Clostridioides difficile infection (CDI) and its recurrence
Key Mechanisms
Neutralization of C. difficile toxin B (TcdB) via monoclonal antibody AZD5148 binding to the glucosyltransferase domain (GTD) epitope
Target Population
Patients at risk of primary or recurrent C. difficile infection globally
Care Setting
Clinical settings managing CDI, including outpatient and inpatient care
Key Highlights
AZD5148 binds a highly conserved epitope on the TcdB glucosyltransferase domain with 99.58% conservation across 9134 global C. difficile genomes.
AZD5148 demonstrates broad in vitro neutralization against multiple recent C. difficile ribotypes, outperforming bezlotoxumab in epitope conservation.
The AZD5148 epitope conservation suggests low likelihood of neutralization escape due to genotypic variation in circulating C. difficile strains.
Guideline-Based Recommendations
Diagnosis
Diagnosis of CDI should consider clinical presentation and laboratory confirmation of C. difficile toxin presence.
Management
Targeting TcdB with neutralizing monoclonal antibodies like AZD5148 may provide prevention of CDI recurrence.
New therapies such as fecal microbiota transplant products are approved but monoclonal antibodies offer an alternative with favorable safety and microbiome sparing.
Monitoring & Follow-up
Monitor for CDI recurrence, especially after initial episodes, given increased risk with subsequent recurrences.
Risks
Risk of CDI recurrence increases substantially after the first recurrence.
Current monoclonal antibody bezlotoxumab has been withdrawn; AZD5148 represents a potential future therapeutic option pending clinical validation.
Patient & Prescribing Data
Patients with primary or recurrent C. difficile infection at risk of recurrence
AZD5148 targets a conserved epitope on TcdB, potentially offering broad protection against diverse C. difficile strains with a favorable safety profile and ease of administration.
Clinical Best Practices
Consider monoclonal antibody therapy targeting TcdB for prevention of CDI recurrence.
Utilize molecular epidemiology data to understand circulating C. difficile ribotypes and their toxin variants.
Incorporate in vitro neutralization data to guide therapeutic antibody development and selection.
by Kelly Ann Mahool, Emily Nguyen, Victoria Godfrey, Ann Marie Stanley, Tyler Brady, Adam Gamson, Kim Rosenthal, Justin Green, Ondrej Podlaha, Bret R Sellman, Christine Tkaczyk, Vancheswaran Gopalakrishnan
